Proteasome inhibition and Parkinson's disease modeling
Proteasome inhibition and Parkinson's disease modeling
复制标题
DOI：
10.1002/ana.20937
复制
发表时间：
2006-08-01
影响因子：
11.2
通讯作者：
Przedborski, Serge
中科院分区：
文献类型：
--
作者：
Bove, Jordi;Zhou, Chun;Przedborski, Serge
蛋白酶体功能受损是多巴胺能神经元退行性变的潜在机制。为了模拟这种分子缺陷，我们给啮齿动物系统地施用可逆的亲脂性蛋白酶体抑制剂，carbobenzoxy- l-异亮氨酸- γ -t-丁基- lglutamyl -l -alanyl- l- leucinal （PSI）。与之前的报告相反，这种方法未能在大鼠或小鼠中引起任何可检测的行为或神经病理异常。虽然理论上很有吸引力，但这种帕金森病的特殊模型似乎表现出较差的可重复性。
Impaired proteasome function is a potential mechanism for dopaminergic neuron degeneration. To model this molecular defect, we administered systemically the reversible lipophilic proteasome inhibitor, carbobenzoxy-L-isoleucyl-gamma-t-butyl-Lglutamyl-L-alanyl-L-leucinal (PSI), to rodents. In contrast to a previous report, this approach failed to cause any detectable behavioral or neuropathological abnormality in either rats or mice. Although theoretically appealing, this specific model of Parkinson's disease appears to exhibit poor reproducibility.